Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13055402 | 0.92 | CYP17A1 (0.59) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL20865536 | 0.86 | CYP17A1 (0.68) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL23619661 | 0.86 | SMN1; SMN2 (0.62) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL730480 | 0.85 | CYP17A1 (0.57) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL1455948 | 0.85 | CYP17A1 (0.54) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL437131 | 0.85 | CYP17A1 (0.54) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL11925396 | 0.85 | SMN1; SMN2 (0.66) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL178373 | 0.85 | CYP17A1 (0.54) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL718380 | 0.83 | CYP17A1 (0.52) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL632848 | 0.83 | MEN1 (0.54) | CYP17A1PSMB8NAMPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807436-B1 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2502941-A1 | Heterobifunctional poly (ethylene glycol) and uses thereof | Intezyne Technologies Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8268936-B2 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120196989-A1 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2348096-A2 | Synthesis of hybrid block copolymers and uses thereof | Intezyne Technologies Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110124840-A1 | Synthesis of Homopolymers and Block Copolymers | INTEZYNE TECHNOLOGIES, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110021718-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES (US) | 2011-01-27 | — | — | US | disclosed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2067801-A1 | Synthesis of Hybrid Block Copolymers | Intezyne Technologies Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1848460-A2 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | Intezyne Technologies Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1807436-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | Intezyne Technologies Incorporated (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006086325-A2 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060172914-A1 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-08-03 | — | — | US | disclosed |
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006047419-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | GNE, ALG1, EPHX2 | CYP17A1 1412/4885PSMB8 1431/4885NAMPT 2831/4885 |
| US-20110124840-A1 | Synthesis of Homopolymers and Block Copolymers | PARG, PCNA, PARN | CYP17A1 2707/4885PSMB8 1521/4885NAMPT 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.